Q3 2022 FMC Corp Earnings Call
Should you need assistance. Please signal a conference specialist by pressing the star key followed by zero. After today's prepared remarks, there will be an opportunity to ask questions to be placed in the Q&A queue. Please press star followed by one on your telephone keypad.
You're using a speaker phone please remember to pick up your handset before pressing the keys.
I would now like to turn the conference over to Mr. Zac and Jackie Director of Investor Relations with FMC Corporation. Please go ahead.
Thank you, Jason and good morning, everyone.
To FMC Corporation third quarter earnings call. Joining me today are Mark Douglas, President and Chief Executive Officer, and understand it Burke Executive Vice President and Chief Financial Officer.
Mark will review, our third quarter performance and provide an outlook for the rest of the year as well as an early view of 2023.
We will provide an overview of select financial results. Following their prepared remarks, we will take questions.
Our earnings release, and today's slide presentation are available on our website and the prepared remarks from today's discussion will be made available after the call.
Let me remind you that today's presentation and discussion will include forward looking statements that are subject to various risks and uncertainties concerning specific factors, including but not limited to those factors.
Identified in our earnings release and in our filings with the Securities and Exchange Commission.
Information presented represents our best judgment based on today's understanding actual results may vary based upon these risks and uncertainties.
Today's discussion and the supporting materials will include references to adjusted EPS.
EBITDA adjusted cash from operations free cash flow net debt and organic revenue growth all of which are non-GAAP financial measures.
Please note that as used in today's discussion earnings means adjusted earnings and EBITDA means adjusted EBITDA, a reconciliation and definition of these terms as well as other non-GAAP financial terms to which we may refer during today's conference call are provided on our website with that I will now turn the call over to Mark.
Thank you Zach and good morning, everyone.
Fmc's strong growth continued in the third quarter with a robust start to the Latin American season, as well as solid pricing actions across all regions driving our results.
New products gained momentum in the quarter growing 26% year over year.
As expected Q3 saw the highest year over year cost inflation for 2022.
Looking to Q4, we all see in sequentially lower inflation across the supply chain.
With this in mind, we expect a strong finish to the year and remain confident in our ability to deliver our fourth quarter and full year forecast.
Our Q3 results are detailed on slides three four and five.
Revenue was up 19% organically EBITDA down, 11% and EPS down 14%.
As expected these declines in the quarter were driven by the highest cost inflation this year, which more than offset the good start to the Latin American season in average global price increases of 7%.
Adjusted earnings were $1 23 per diluted share in the quarter 13 cents above the midpoint of our guidance range with the vast majority of the outperformance driven by higher EBITDA.
We delivered double digit year over year growth across the portfolio, including 23% growth in herbicides, 19% in fungicides and 10% in insecticides.
Third quarter sales were $1 $38 billion led by volume growth in Latin America, or North America, as well as price increases across all regions.
In North America sales increased 21% year over year.
Besides grew rapidly in the quarter, especially on cold in the Midwest.
Overall performance in the Midwest across corn, soybeans, and other crops more than offset lower diamide sales in the west due to drought conditions.
In Latin America sales increased 35% year over year led by Brazil and Argentina.
With the backdrop of strong commodity prices and increase in acres grow our confidence in the region is high.
Our results were driven by a robust start to the new season with strong selective herbicide and insecticides sales price increases and expanding market access.
FMC has been investing and expanding market access by adding commercial resources and developing new broader relationships with large cooperatives and distributors.
These investments are focused on key row crops, such as soybean and corn and we are starting to realize the results benefit from these increased sales.
As an example by center based insecticides, including those used to control stink bugs in soybeans with the largest growth driver in the region for the quarter.
We also successfully launched on Suva flowing to peer based fungicide for soybeans and peanuts in Argentina, and Paraguay during the quarter.
This is the second new molecule from Fmc's pipeline. Following the successful introduction of Isa Flex herbicide in Australia last year.
Turning to EMEA third quarter sales were down 12% versus prior year and were up 1% organically.
In addition to strong pricing results were driven by increased demand for <unk> on fruit and vegetables, and herbicides on cereals, and oilseed rape FX.
FX was a significant headwind in the quarter.
Fmc's decision to exit the Russian market. The first major crop protection companies to do so early this year.
Had an approximately $8 million negative impact on EBITDA in the quarter.
And finally Asia was down 6% versus the third quarter last year and up 2% organically pricing gains were more than offset by FX headwinds floods in Pakistan and erratic weather in India and other countries impacted performance in the quarter.
However, demand remains strong for new products based on <unk> and other Chemistries and FMC continues to make significant progress in improving our market access in geographies, where we are and have represented such as Indonesia, Vietnam and Thailand.
Investments to expand market access have not been limited to Latin America and Asia. We have also invested in market expansions in the U S, Turkey and several other countries.
This is an important element of our growth strategy and includes scaling up of Fmc's Technical service organization, expanding our sales force pursuing new collaborations with distribution partners and other steps that are beginning to deliver market share gains.
These initiatives become even more important as we continue to introduce novel technologies that require close engagement with growers.
Overall, adjusted EBITDA for the third quarter was $261 million.
A decrease of 11% compared to the prior year period, but $6 million above the high end of our guidance range, primarily due to somewhat lower cost inflation than we previously anticipated.
As forecasted cost and FX headwinds more than offset price increases and volume gains.
Average price increases of 7% contributed $85 million in the quarter.
We are seeing initial signs of decelerating inflation, but we are confident the cost headwinds in 2000 to have peaked in the third quarter.
FX was a $25 million EBITDA headwind in the quarter due to weakening of several currencies around the world.
Moving to slide six and Fmc's full year, 2022% and fourth quarter earnings outlook.
With continued strength in market demand and the success of pricing actions to help offset cost increases and FX headwinds. We are raising full year 2022 revenue to a range of $5 $6 billion to $5 8 billion representing.
Representing an increase of 13% at the midpoint versus 2021.
Sales growth was driven by volume and price in all regions, partially offset by foreign currency impacts.
We are narrowing the full year adjusted EBITDA range to $1 37 billion to $1 $43 billion Rep.
Representing 7% year over year growth at the midpoint, reflecting the confidence in our order book and supply availability.
The range for 2022 adjusted earnings per share is narrowed as well and is now expected to be $7 10 to $7 60 per diluted share representing an increase of 7% year over year at the midpoint.
Consistent with past practice, we do not factor in any benefit from potential share repurchases in our EPS guidance.
Guidance for Q4 implies year over year sales growth of 8% at the midpoint compared to the prior year period.
Pricing momentum of volume growth are expected to more than offset FX headwinds in the quarter.
We have good visibility into demand for the quarter with strong order books for both the Brazilian and U S markets.
Cost increases are forecasted to be lower in Q4 compared to Q3.
The combination of sales growth and lower cost headwinds as anticipated to result in EBITDA growth of 15% at the midpoint with EPS up 9% at the midpoint year over year.
Moving now to the updated drivers of 2022 EBITDAR outcomes on slide seven.
Market growth is expected to remain in the mid to high single digit range and we are seeing cost inflation beginning to decelerate.
We are successful in mitigating the impact of lost sales from our decision to exit Russia and have good visibility into supply to fulfill fourth quarter demand.
Full year price increases of mid to high single digit and strong volume growth are expected to more than offset cost and FX headwinds keeping the midpoint of our guidance unchanged at $1 4 billion.
I'll now turn the call over to Andrew.
Thanks, Mark let me start this morning with a quick discussion of two accounting changes we implemented on July one.
First we changed our method for costing inventory in the United States from the last in first out or LIFO cost method to the firsthand first out or FIFO cost method consistent with how we account for inventory across the rest of our global business.
This is the primary change made and the only one that impacts prior year reported earnings and EBITDA.
Second we changed our method of accounting for the determination of the market related value for a class of assets within our qualified U S defined benefit plan impacting our net periodic pension costs.
This change only impacts our historical GAAP result, as we exclude nonoperating pension charges from our adjusted results.
Certain prior year amounts within the earnings tables included with our earnings release today have been recast to reflect these accounting policy changes.
Impacts to our recast at income statement are not material.
Further detail on both of these changes are included in our third quarter 2022 Form 10-Q, which we filed later today. Additionally.
Additionally, we have included a table in the appendix of today's slide it shows recast it adjusted EBITDA earnings and EPS for 2021 for easy reference.
There were no impacts on our reported results for Q1 or Q2 2022 from these changes.
With that let's shift to a review of some key income statement items.
FX was a headwind to revenue growth in the third quarter as expected driven by weakness in European and Asian currencies, particularly the euro Indian rupee and Turkish lira.
We continue to anticipate FX headwinds for the remainder of 2022, driven by Asian and European currencies.
Interest expense for the third quarter was $41 8 million up $8 $7 million versus the prior year period, primarily due to higher short term interest rates and to a lesser degree higher debt balances, partially offset by savings from the refinancing activity completed in the fourth quarter of last year.
With rapidly rising interest rates, especially in the United States. We now expect interest expense for full year 2022 to be in the range of $148 million to $154 million, an increase of $6 million at the midpoint compared to our prior guidance.
Our effective tax rate on adjusted earnings for the third quarter was 14% in line with our continued expectation for a full year tax rate in the range of 13% to 15%.
Moving next to the balance sheet and liquidity.
Gross debt at quarter end was approximately $3 6 billion.
Up nearly $390 million from year end 2021.
Gross debt to trailing 12 month EBITDA was two six times at the end of the third quarter, while net debt to EBITDA was two four times.
We continue to expect full year average leverage and our targeted two 4% to two.
Five times gross or two 3% to two four times net ranges.
Moving onto cash flow on slide eight.
Third quarter year to date free cash flow was negative $139 million.
Adjusted cash from operations of $16 million was down $290 million compared to the prior year period, driven by higher working capital.
<unk> sales growth was the largest driver of increased cash consumption for working capital.
Capital additions in other investing activities of $103 million were slightly higher than the prior year period.
Legacy and transformation spending was down $6 million with slightly higher legacy expenses more than offset by the absence of transformation spending this year.
We are lowering the range of our full year 2022 free cash flow guidance to a range of $440 million to $560 million a reduction of $125 million at the midpoint.
Adjusted cash from operations is now expected to be in the range of $650 million to $710 million, a reduction of $150 million at the midpoint compared to the prior year.
Reflecting higher cash consumed by working capital than previously guided.
The vast majority of the higher expected consumption of cash by working capital is due to the higher sales now expected in the fourth quarter, none of which will be collected in the current year.
The remainder of the increased cash consumption stems from maintaining year end inventory level to support anticipated strong start to 2023, despite the higher Q4 sales.
As well as from other impacts of the current inflationary environment on working capital.
Our guidance for capital additions have been reduced by $25 million at the midpoint with capital additions now expected to be in the range of $125 million to $145 million.
Legacy and transformation guidance is narrowed to a range of $40 million to $50 million unchanged at the midpoint.
With this guidance, we anticipate free cash flow conversion from adjusted earnings of 54% at the midpoint with conversion limited this year by the impact of rapid sales growth and inflation on working capital.
Rolling three year free cash flow conversion is now expected to be 67% for 2020 through 2022.
Somewhat below our targeted 70% to 80%.
We anticipate reverting to the targeted cash conversion range in 2023 as the impact of this year's rapid inflation and price increases move through our working capital.
Moving on to cash deployment.
No shares were repurchased in the third quarter, we paid $67 million in dividends.
In the first several weeks of October we repurchased 875000 FMC shares at an average price of $114 22 per.
Per share for a total of $100 million.
Year to date, we have deployed roughly $490 million of cash approximately $190 million for the <unk> acquisition $200 million in dividends and $100 million in share repurchases completed in October .
We paid down an additional $67 million in dividends on October 20th and we expect to return up to an additional $100 million to shareholders through share repurchases and the remainder of the fourth quarter.
For a total of up to approximately $470 million in cash returned to shareholders and approximately $660 million of total cash deployed in 2022.
And with that I'll hand, the call back to Mark.
Thank you Andrew turning to slides nine and 10 I want to provide an early look at the key market and cost dynamics underpinning our emerging view of next year.
Soft commodity prices remained robust in stock to use ratios for key crops remain below the average for the past decade.
Growers around the World will continue to rely on our advanced technologies to deliver high yields while they comeback erratic weather and persistent drought conditions.
As a result, we expect the overall crop protection market will grow in the low to mid single digit range next year on a us dollar basis. Please.
This favorable backdrop combined with our continued pricing actions strong demand for our newest technologies from further market access gains will provide solid support for profitable growth in 2023.
There have been significant cumulative cost and FX headwinds to EBITDA over the past couple of years, which we intend to recoup through pricing and lower costs going forward.
Clearly all the recovery will not take place within a single year, but we expect to shift to improving margins in the second half of 2023.
Headwinds to the top line will come from FX volatility as well as a normal range of registration losses.
Potential factors that could drive 2023 revenue higher include stronger market growth, that's a pricing or product mix and a reduction in FX volatility.
On the supply front, we expect greater stability as we continue diversifying our raw materials sources.
Experienced fewer disruptions.
Input cost inflation is expected to decelerate and hence input costs are expected to become a year over year tailwind in the second half of the year.
In fact, we're already seeing improvements in the availability and cost of logistics.
Regarding internal costs, SG&A, and R&D expenses will grow at or below the rate of sales growth.
Investments will be focused on commercializing new products expanding market access in developing new chemical and biological solutions.
Potential factors that could drive 2023, EBITDA higher include faster than expected easing of input costs and the potential for improved SG&A leverage.
Taking all of this into consideration, we expect Fmc's growth momentum will continue throughout next year with margin expansion in the second half of 2023.
To conclude the second half of 2022 is playing out largely as forecasted we delivered solid results in the third quarter, Despite peak cost headwinds.
For full year 2022, we expect to deliver another record performance.
FMC has thrived in a year of unprecedented challenges.
Our team successfully navigated logistics bottlenecks around the world.
We have made steady progress de risking our global supply base, which we will continue to do next year.
We have maintained disciplined controls on discretionary spending and at the same time, we continue to invest in the future with the acquisition of Biopharma, which enhances our biologicals platform as well as increased investments in R&D.
Finally, our continued investments to expand Fmc's market access in key regions and countries are producing strong results and market share gains.
Looking to 2023, we are optimistic based on what we see at this point.
Protection fundamentals appear to be positive for next year, which bodes well for market demand across our existing portfolio.
New product introductions based on our latest technologies as well as new biological solutions are doing extremely well and they will drive mix improvement.
We are seeing signs that raw materials logistics and supply challenges will continue to ease next year, providing a positive tailwind to margins in the second half of 2023.
Once again, when we look at the full picture for 2023, we remain upbeat on market fundamentals and the performance we expect to deliver.
I'll now turn the call back to the operator for questions.
We will now begin the question and answer session.
We placed in the queue. Please press the star key and then one on your Touchtone phone.
If you're using a speaker phone. Please remember to pick up your handset before pressing the keys. Please limit yourself to one question and one follow up if you have additional questions you can jump back in the queue to withdraw from the queue. Please press star and then two.
At this time, we will pause momentarily to assemble our roster.
Our first question is from Lauren <unk>.
With BNP.
Line is now open.
Yes. Good morning, Thanks for taking my question.
My question is regarding the cost inflation, you're talking about for each one and then it was counting towards visibility on this.
Was wondering if you could talk about the magnitude of this inflation, which it seems to me that.
So imagine that youre not confident to grow demand and for the full year I think the choice of why it is interesting you were talking about margin expansion units to non solid full year. I was wondering if you could talk a little bit about this thank you.
Yes, certainly laurel.
Well first of all let me clear up that little misunderstanding, we do expect margins to improve as we exit 2023 versus where we are today in 2022. So margins will improve next year I think that's an important point because we have been talking about first half versus second half, but full year will be positive.
Obviously, we've described quite.
Quite a few times how costs flow through our P&L the.
The materials that we're buying in the second half of this year give.
It gives us very good insight into the cost for the first half of next year.
We are seeing costs still higher than they were but the rate of increase is slowing down and that's very important because that what that tells us is that as we enter the first half of next year. The materials that we will be the volume and the cost to flow through the P&L in the second half of the year will be lower.
So that's how we see the first half second half so costco from being somewhat of a headwind in the first half to somewhat of a tailwind in the second half now when we talk about the full year.
We don't have a budget at this point. So we are giving what we describe as an early look at next year.
I think though that when you think about our five year plan that we put in place in 2018.
Our topline of 5% to 7% growth in our seven 7% to 9% growth on the bottom line there, they're very much where we're thinking we can be next year.
When you think about the slides that we put out there in terms of the cost dynamic in the market dynamics market dynamics are pretty positive for us. So if you think about the following.
If you think about price up next year in the sort of low to mid single digit range. You think of volume the same in the low to mid single digit range, you've got some registration lawsuit and you've got a market that's growing in the low to mid single digit range you take that you take.
<unk> headwind probably in the low to mid single digit it's quite easy to see has been within the middle to the upper end of that 5% to 7% range and that's how we're sort of modeling it at the very early stages.
We described in the slides things that can move us up and down and if we're in that range and then obviously, we're going to get EBITDA leverage and you should see EBITDA in that 7% to 9% range as well as the improved margins. So the algorithm works I'm confident in what we see in terms of our own portfolio of new product introductions.
And next year.
It is a volatile world, but we all we are pretty confident about what we see next CLO.
Thanks, Marc and I was just wondering that we're getting more Q4 and a wide range I was wondering if the uncertainty Dan reasonable about how much of an early season, you get into 'twenty three in another <unk> or to what extent <unk> thousand any stance that you've found any credible in Q3 and inventories might.
It's high end. So then for Q4, but he just 90, maybe a little bit.
I guess that's risks.
No.
The range.
Yeah. So seriously we have a we have a range for a reason we don't necessarily see that range is wide. There are a lot of things going on in the world right now as we all know I would say the season in Latin America. As we've said has started well we plan for that in Q3.
We took advantage of that.
We expect it to continue in Latin America as we go through.
Q4, and Q1. It is it is a strange time of the year because not only is the Latin American season in full swing, but things are moving in North America things are starting to move in Europe ahead of the season. So it's a time of volatility in demand and as we've said before we tend to look at the years into hubs well that applies to.
Q4, and Q1, so yes, there is a range there, but we don't consider it too broad.
We're confident of our ability to deliver on on Q4 looks good in Latin America looks good in North America, and Europe is gearing up well. So overall I think the midpoint is where we said we would be for the full year, we really haven't changed the second half at all.
You've seen that in the numbers, it's going to be a good second half for us. So I think the range is appropriate for what we see in terms of what's going on in the world.
Thank you Mike.
Our next question comes from Christopher Parkinson with Mizuho. Your line is now open.
Awesome. Thank you so much mark could you just give us a preliminary glimpse on just how youre thinking about it from just perhaps just a top down perspective on the growth rates for the Diamide.
Plant health on new products, including full end up here and just yes, I think you said registration losses would be more or less in line with historical averages.
Any preliminary thoughts on how we should be thinking about that throughout the balance of 2023. Thank you very much.
Yes, Chris could you just repeat the first piece of your question, we Didnt hear it.
Oh I'm sorry, no I was just asking you about potentially parse out.
Your preliminary thoughts on growth rates for the Diamide your plant in our portfolio and new products, just just broad based thinking of how youre assessing that thank you.
Thanks, Chris Yeah. So let me take let me take the Diamide fast this.
This year year to date, we're up in the.
In the high mid single digits, we would expect that same growth rate next year as we go forward, we're getting new registrations, especially for <unk>.
That market is growing rapidly in many parts of the world, which is good news.
On new products, the new products are about $600 million. This year in terms of overall revenue were about 10% of revenue. We would expect that to increase next year I don't have the exact amount, but I would expect it to move upwards in terms of overall revenue certainly given the strength of what we've seen over the last couple of years with new product.
<unk>.
And then the plant health business is doing extremely well.
It's growing north of 20% this year biological is growing even faster than that I would expect that business to continue growth of north of 20% as we go into next year, driven mainly by biologicals, So overall that whole.
That whole.
New product mix that we have going through the business is getting stronger every year.
It's interesting when you think about it we closed.
The Dupont deal five years ago. This week, which is frankly hard to believe but the $600 million.
Of what we call products launched in the last five years of all been put in the marketplace since that acquisition. So it just shows the power of that innovation engine that we have and it's certainly been accelerating as we've gone over those five years, so more to come from that pipeline, but hopefully that gives you a sort of a flavor of how the three pieces fall out.
No.
That's very helpful and just as a quick follow up.
We aggregate the.
Quarterly cost headwinds so the recent $169 million in <unk>, you know, you've got plus or minus $3 79 year to date.
Part of that is raw materials part of that I believe transportation logistics and part of that is also correct me if I'm wrong operating on <unk>.
Procuring certain raw materials that are off contract.
In addition to this let's say standardized.
Potential for raws to rollover, how should we think about the other parts of that so in terms of better.
Optimizing procurement from your core suppliers and then also transportation in terms of freight cost and everything else. Just if you have any other details on that that would also be incredibly helpful. Thank you.
Yeah. Thanks, I'll give you I'll give you a high level view and then Andrew if you want to make a couple of comments listen I think we've been in such a period that we've never seen before in terms of volatility.
Moving in supply that we're very hopeful that as we get into 2023 was starting to enter into more of a stable environment in terms of how we operate that has many benefits obviously stress on the organization is an important one but second is costs because it allows us to go back and get materials from what we.
We call out Prime resources, where we have the <unk>.
Conditions, the best terms the best pricing.
We are seeing and I just said it in the script, we all see in logistics costs freeing up obviously.
We're all pretty much aware that the world is entering into a recessionary period. There is less goods moving around the world. What does that mean it means container space is freed up it means lowest maritime shipments, we're seeing lower costs for rail road freight in different parts of the world and where we sparingly use air freight those costs are coming down as well.
So we are seeing the whole cost complex around logistics getting better Andrew do you want to make any other comment yes, I think we've talked in the past about the makeup of our cost headwinds you know the largest piece being active ingredients or intermediates used to produce them. You know that was a very specific to FMC into our product mix. So while certainly I think people are <unk>.
Some cost turning in certain commodity chemical categories for example.
The nature of that most of our cost headwind has really been around the supply demand dynamics and disruption of availability for these very specialized intermediates and active ingredients that we purchase.
The decrease in disruption that Mark referenced is starting to give that benefit of allowing us to re concentrate purchases back on strategic suppliers and Thats why were expecting to see the turn.
That is our biggest cost bucket in these raw materials for active ingredients and intermediates.
It's also the slowest to flow through our P&L. So.
So that's why it takes the longest time to react to changes, but we do see some good reasons to be optimistic that packaging is our second largest and much smaller but second largest cost bucket, it's still very mixed.
Where we've seen some reduction in input raw material costs in certain parts of the world, but some still some disruptions in availability. There is still a mixed area for us and an area, where we are optimistic to see improvement going into 2023.
And then as Mark commented certainly on logistics, which is the smallest of the three buckets, but the one that would flow through our P&L. Most quickly we are seeing some signs of improvement.
Both in Ocean and air as well as in rail in terms of availability and cost.
Very helpful. Thank you so much.
Thanks, Chris.
Our next question comes from Vincent Andrews with Morgan Stanley . Your line is now open.
Thank you good morning, everyone I wanted to follow up on the price comments for 2023, if I've got my math right you guys have been achieving a high single digit pricing year to date very strong it seems like you've got a good uptake from your customers. So if you're talking about low single digits into next year I assume that that's a new round of pricing that you're anticipating.
<unk> introduced saying and I'm just wondering because its you know its only really November and you don't have your plan yet is that just sort of a placeholder and you Havent decided exactly how much price. It takes for next year or just sort of what is the pricing philosophy for next year does it does it vary by region.
Yes, Thanks, Susan yes, it does vary by region.
I think there is in the method of how we implement prices in certain parts of the world such as Europe or the U S. We have a price book that goes out before the season starts and all all sales are based upon those price books now over the last two years, we have actually changed mid seasons because of just the scale of.
What we see.
In other parts of the world.
The cost.
The prices move constantly so it's not as if you have a price youre moving prices constantly so the way we see next year, we are definitely moving prices, we already have in the U S.
We are in Europe as well, we're also moving in parts of Asia. So we're on we're on the track to recoup the EBITDA that we've had the compression with over the last couple of years and as I said, we're not going to get that all back in one year. So $23 24 will be the years of us.
Coming down the other side of that curve as we hold price and raise price in certain parts of the world. So yes, I think the basic answer is we continue to be aggressive on pricing. We've had margin compression that we don't like and we're going to get those margins back.
Okay, and then just on the new market initiatives, obviously I know this has been important.
Initiative and now Youre, starting to see the results and I'm just wondering as you see those results or is it sort of creating new opportunities or new lines of sight on other things you can do within those markets with other molecules.
Just as the opportunity set broadening I guess, that's my question.
Yeah listen I think once you start down the road of expanding where you're actually selling than growth rates accelerated and that's what we've seen up I'll just give you a little factoid that we talked about growth in Latin America have been very strong 50% of our growth in Brazil in the third quarter was our new <unk>.
Get access so what does that basically mean it means we're selling onto new acres that we never sold them to before we're selling to broader distributors and co ops with deeper relationships and we're selling a portfolio that is somewhat different to what we've sold default for instance, I talked about the <unk> based products full stink bugs.
That is a big problem in the Brazilian soybean market, we have the best solution. So we're expanding our sales into new areas U S is another good example.
We've added a number of salespeople and service people over the last 12 months that means we're calling on more retailers with calling on different distribution outlets and we're getting our portfolio into hands that have never been in that before so when you think about fmc's price and volume growth.
That volume growth is not to the same customers. The volume growth is going to new people new markets new acres, new crops that we've not been on before so we see that as something very positive and I would say that we're at the beginning of a multiyear effort by FMC to really improve our market access which will improve our market share in <unk>.
Great ability I'm very happy with what I see today, obviously, we have to train new salespeople, we have to train Tech service, but what within a 12 month period. Good salespeople start to get returns and we're seeing that now.
It sounds great. Thank you very much.
Thanks Vincent.
Our next question comes from Kevin Mccarthy with ERP. Your line is now open.
Yes, good morning, Mark I think you've closed on the Biopharma deal and owned it for maybe three or four months at this point. So can you provide an update on what you're seeing in that business and your level of confidence in the strategy too.
Leverage the technology across major crops with an eye towards your goal of $1 billion in sales by 2030 and more broadly what are you seeing in the pipeline as it relates to <unk>.
Future inorganic growth potential for your biologicals platform.
Yes, thanks, Kevin.
It's hard to believe that we've owned the business for three or four months.
There's been a lot of progress first of all on integration integration has gone very smoothly.
The good news is that all biologicals platform.
Health platform is based in Copenhagen, which is web <unk> federal based.
About four or five kilometers apart from each other so that's working really well as being very good dialogue that I think the most important thing that I can tell you is that we made our first commercial sales in the last three to four months, we made our first commercial batches of one product and we've actually scaled up a second product. So the timing was very.
Good for us it allowed us to integrate and get the first commercial sales that's an important step to prove that the technology works and customers are willing to buy that technology is very important.
The pipeline is pretty much as what we said it was we have five products in.
In research today, and then moving through at the rate that we would expect I think the most important other aspect is manufacturing strategy. This is fermentation and it has new technology to FMC.
Our manufacturing groups or hiring people right now with fermentation capabilities to augment what <unk> federal half and we're making great progress on our strategy for where are we going to manufacture or are we going to do it ourselves or we're doing it with third parties is it a combination so all of that is going very well.
Second part of your question Kevin regarding the the.
Inorganic opportunities for M&A, we do have a number of targets that we're looking at today from a plant health perspective, they all based around the biologicals platform I'm not going to say anymore than that.
This is and I've said it numerous times that this is an area of focus for FMC not only from an M&A perspective, but from our ventures group as well I think many of you know that we set up a ventures group about two and a half years ago actually Biopharma was one of the first companies that we have invested in we do have other investments in it.
Peptides that are going very well these are new areas for biologicals to be used as pesticides. So I expect to see more from us on the M&A front.
Thank you for that and then secondly, if I may.
Are you seeing inventory levels that you would describe as outlying either in terms of being too high or too low.
And any of your major markets Nowadays.
Well I think generally speaking overall, we would say we're happy where inventory levels are in the marketplace. There are pockets of higher inventories, we've talked about India before.
The last few years with the way the monsoons played out and rice acreage reductions have not been great. So we're working through inventory the I would say in the U S. Things are fine in Europe is pretty okay for us.
One or two pockets in the south because of the dry weather that we had last year.
Say in Latin America.
There are parts of Brazilian market, where they had a drought last year that you can imagine inventories are high images are high right now in Brazil, because we're in the we're in the planting season, but we're happy with where our inventories are right now.
Thanks very much.
Okay.
Our next question comes from Joel Jackson with BMO. Your line is now open.
Hey, Mark.
Andrew Youre not going to like a question I'm going to try to connect the dots to what you said. So you said you're on pace to hit the five year target that you set in 2018 for 2023, if I take 8%. After 2018 EBITDA CAGR that that's about one six something billion EBITDA next year, and I think you said well, but youre on page three.
Nothing you say wouldn't take you out of the range got normal 7% to 9% growth rate off of this year that would imply a $1 5 billion EBITDA next year can you clarify your comments please.
Yes, I think I think maybe you misunderstood Joel.
I said that next year, we would have.
In the range of five to $7 seven to nine when you look at the five year average worried about 6.5% Rev.
<unk> growth and we're slightly below the EBIT.
Number four.
The last four years I think we're about we're at one four and I think our forecast for 2022 and the long range plan was $1 45, but if you back out Russia were up one four to five so with $25 million below a $1 45 billion, it's not a lot.
So when you think about the significant cost we've had and I think through the planning period, where over $1 billion of costs and FX, Andrew is that correct right and EBITDA I think.
Joe I'll, just put a couple of markers down well.
Our five year goals at the midpoint of our guidance for this year revenue would be seven 4% compound it.
So above the high end of our 5% to 7% range that we target over that time period EBITDA is just about 6% at the midpoint and as Mark pointed out that's after swallowing 25 million in lost EBIT.
By the exit of our Russian business as you know.
Absent that decision a little bit better.
I think the comments earlier on the call and in the script, our Denmark made around the five to 779 very specifically to single year of 2023, we think that relationship of topline and bottom line for the top line grows at a multiple of the overall market with a balance of pricing and volume and where the bottom line grows faster and we see mark.
Expansion, particularly in the second half as we've discussed some of those dynamics is the right way to be thinking about 2023.
Echo marks earlier comment we don't have a budget yet we're in the midst of that rollout process. This is from you know working through that process and I think a recognition of a very strong market backdrop that we're operating in right now and I think a good some good signs of momentum in the right direction around cost and continued strength with volume.
Okay, and then my follow up would be I believe a small two parter. So I think capex went down $25 million. This year with that mean, we're going to have more capex next year and then if you've got inflation hurting networking capital gets here its brought down your free cash flow are you expecting extra to have some very positive.
<unk> net working capital and free cash flow.
So let me hit both pieces I think yes, we did bring down the midpoint of our Capex Capex guidance is here about $25 million, that's really driven by availability of materials and labor to do the projects we have in the pipeline.
We still think 150 to 175 is the right range steady state.
For our for our.
And it's also limited by on our own internal capability to execute so I don't expect some big step up in Capex next year, but at $1 50 to 175 is probably a more normalized range looking at 'twenty three and beyond.
In terms of the working capital impacts on cash flow look where we're dealing with massive cost inflation and large price increases.
At the midpoint is $650 million in sales growth this year.
Given our cash cycle, it's going to take a little while to catch back up and have that flow all the way through and be collected.
With the higher sales in Q4.
Yes.
<unk> is that where the markets we sell in in Q4, such that you don't collect on those sales in the same quarter. So that's the reason for that the decrement down and free cash flow. This year as I commented in the script.
Echo here, we do expect to revert back to the more normal 70% to 80% conversion range next year.
As we work through some of that and catch up on some of that inflation in working capital.
We are still expecting some inflation in costs next year, we are expecting to continue raising prices next year, but at a lower rate. So it should not be the same substantial headwind and cash that we have this year.
It really is that just catching up on you know very very rapid inflation and price escalation, that's hitting our working capital in the short term.
Thank you.
Thanks.
Our next question comes from Adam Samuelson with Goldman Sachs. Your line is now open.
Oh, yes. Thank you good morning, everyone.
Maybe following up on <unk>.
On Joe's line of questioning on the growth and I'm just trying to connect with.
This concept of.
Price cost and FX has been a kind of multiyear headwind.
To the business and this idea that.
We do think there is potential to catch up and I just wanted to.
Just clarify because if that does actually occur.
I presume that would get you to a year, where you are.
Have scope to exceed that.
Kind of 7% to 9% EBITDA growth algorithm.
And especially I'm trying to think on a year on year basis.
There is the absence of these.
Secondary supplier sourcing, which are incremental costs, you're incurring to.
To drive volume.
<unk> to recoup the absence of that can be.
A bigger tailwind I'm, just trying to connect kind of.
If we can actually when can we actually think get caught up on price costs.
<unk> kind of the net of those three and which has been.
Pretty sizable headwind for the last couple of years.
Yes.
I think.
We've been pretty explicit that I would say.
We're starting to see some of that in Q4.
You'll see more of it as we start to go through next year, but I think where you see the real <unk> is the second half of the year because at that point, we will be continuing to benefit from the price increases and at that point.
If everything goes as we think it should go then prices will actually be coming down in the second half of the year for raw materials logistics et cetera. So that's when we should start to see that acceleration of margin and you will see that continue in through 2020 full so its really six months out from now although we're starting to see the signs of it now.
Andrew would you want to add anything yes, Adam I would just add I think as you think about expectations for 2023 in particular.
<unk> pointed out that shift in cost from being a headwind to a tailwind is likely second half.
And then just the nature of catching up on a cumulative price cost FX.
Relationship that's going to take more than a year to date and market commented on it in our prepared comments that that is not something that's just going to slip switchback immediately we will continue raising prices. We will continue to holding prices as cost begin to decelerate and turn the other direction. That's when we'll see the margin catch up and catch up on that.
<unk> chip.
So could next year be better than 7%, 9% at the Bottomline possible again, we don't have a budget yet, but what we do feel very confident about is that relationship between top line growth at a multiple of the overall market driven by a balance of volume and pricing with leverage to the bottom line, particularly in the second half next year is when we get to.
A reversal of the cost that direction that we've had for past.
Multiple years.
That I think it's something we can feel very confident about going into 2023, even in the absence of a full budget.
Got it and I. Appreciate you don't have a full budget. So this will be something that will get.
Closer scrutiny kind of through the next few months.
So the your outlook in February , but on the SG&A and R&D side and looking at the way, you're saying the cost dynamics talk about labor cost inflation, which is evident but continued investments across kind of all your key kind of investment areas is there any.
Notable.
Sizable step up on the SG&A and R&D side that.
You know in excess of some of the broader inflation that we're seeing that we should be contemplating.
No I don't I don't think so Adam you know, we're investing in R&D at an appropriate rate right now that will step up next year is obviously, we continue introducing new products into our pipeline precision AG is getting the appropriate funding and that is growing well for us.
And then on the SG&A side, we will not slow down on the market access investments around the world and then we have the inflationary rates that we see for our people costs around the world as we go into next year, but I don't think there's anything that I would call a step up Andrew I don't think there's anything no I think at this point, we just guided to we would expect SG&A and R&D to grow.
No faster than sales.
That would allow us plenty of room to continue funding the investments Mark has described deal with inflation and then on the SG&A side in particular, we're continuing to drive leverage out of our back office, we are making investments in customer facing market access areas of SG&A, but in more of the back office business process part.
SG&A for working very hard to continue to drive efficiencies out of it out of the business. So that kind of leverage on sort of back office SG&A. You should also expect to continue.
Alright, that's all Super helpful. I'll pass it on thanks.
Thank you thanks Ed.
Our next question comes from Stephen Byrne with Bank of America. Your line is now open.
Andrew just a couple of minutes ago, you made a comment about.
So we're expecting further cost inflation in the first half of next year.
Is that.
Is that just a year over year comment or do you expect to inflation.
Sequentially from here, Alright, I raise that as well.
<unk> about some active is being sourced from China.
Already deflated significantly.
So can you comment on you know.
What what were your raws.
Inflation in the third quarter year over year in and are you seeing a difference between whether you're sourcing those raws in actives from China versus other parts of the world.
Steve I think great point, but let's parse that in a couple of pieces first when we're talking we've been talking about inflation year on year change. So we expect there to be year on year increase in our costs in the first half of next year, principally based on what we're seeing in raw material Act immigrating.
Intermediates that we are entering purchase orders for right now.
Now.
I think we've tried to highlight but let me reemphasize, we can only speak to the mix of things we buy.
We are aware and I've seen market data on a number of more generic commodity.
Active ingredients are being sourced out of China, where there have been some announced price decreases.
We are buying.
For example, intermediates for Diamide, which are highly specialized and have very few if no other commercial uses.
And very limited number of suppliers that dynamic may be FMC specific I will say this and again, we are seeing a decelerating rate of inflation as we look into the first half although costs will be up year on year.
And as we know that gives us confidence in as we continue to look at how supply disruptions of resolving and how they have been our ability to again to shift more of our production back to preferred suppliers and concentrate the buy a bit relative to what we've been doing the past several quarters.
This confidence that we're going to see this benefit going into the second half.
So again I think cost inflation should be lower in Q4 than it was in Q3 should be lower in the first half next year than it was in Q4 still up year on year and as we get into the second half we start to get to a positive year on year comparison.
That helps.
It does so so what were raws inflation year over year in the third quarter and maybe more broadly.
What limits you from being able to push price.
Not more than 7%.
Two to close that gap are you seeing are you seeing any erosion in discipline from competitors or is it certain regions of the world where certain AGGY.
AG economies that.
Really represent the challenge on pushing price more than that.
That's a lot of price when you're at our size and especially with our EBITDA margins. So for us it's not never going to get all of this back in one or two quarters.
Flow over a period of time and you work your way through back on a on a.
On a same sort of principal at the end of the day, we all refine and specialty chemical company, we're not a commodity chemical company.
It takes us a little bit to get it on one side, but on the other side, we keep it and I think that's an important facet that you have to remember I think Andrew outlined pretty well the inflationary aspects that we're thinking through but for me I think the way we're growing the business and don't forget this year is going to be a record year for us I think we're taking the appropriate actions on price.
We'll continue to do so and in addition, we're gaining market share by our market access activities. So I think the two combined produced very strong results.
And I think Steve just one last comment there you have to think about.
Maintaining that if we continue to have an effective full year price increase next year and our second half cost start declining you'll get that Marc you're starting to get real margin recovery.
So raising prices into that into that are you know, we're basically trying to set the price where we can hold it and hold that margin as costs begin to decelerate and recoup the margin with decelerate in cost and the stickiness of those price increases.
As Mark as Mark mentioned, that's very much that the hallmark of our specialty business as opposed to a commodity.
Thank you.
Yeah.
Our next question comes from our time <unk> with Redburn. Your line is now open.
Hello, and thanks for taking my question I think we've already touched on that a bit.
Getting back to your full year guidance on low to mid single digit growth.
Is that correct to assume that you're penciling in low single digit price increase or is it more like the mid <unk>.
Uh huh.
High single digit growth would you have any comments on that please thank you.
Yes, I think.
I think I said it earlier at the beginning you know when we think about next year.
Reising in that low to mid single digit range volume in the low to mid single digit range is appropriate for how we're thinking our early thinking for next year. So if you are specifically focused on price I would think in that low to mid range.
Alright, thanks, very much just wanted to confirm that thank you.
Thank you.
Our next question comes from Josh Spector with UBS. Your line is now open.
Yeah, Hey, guys. Good morning, two quick ones. If I may just when you talked about diamide gaining momentum in Asia is there a way to think about the penetration of those products in that market versus the rest of world and the runway there and when you talk about increased market access in Latin America, and those people and cost and put in place and how you're going to reap the benefit of that or was that some.
What costs are still ramping thanks.
Thank you yeah most of taking the second one first most of the costs are already been embedded in the in the Latin American business, and we will see those benefits we've seen them already but we will see them accelerate as we go through next year on the Diamide in Asia listen, there's two very big markets for us rice on fruit and vegetables and.
Much every country grows rice in pretty much every country grows fruit and vegetables to highlights in Asia is our biggest market about 50% of the diamide.
Sold in Asia. So you could think about pretty much every country around major markets in rice and fruit and vegetables are the key ones.
Okay. Thank you.
Thank you.
That was our last question so I'll pass the call back over to the management team for closing remarks.
There are no more closing remarks are those all the time that we have for the call today and thank you and have a good day.
Yes.
That concludes the conference call. Thank you for your participation you may now disconnect your lines.